Incyte [INCY] vs Alnylam [ALNY] Detailed Stock Comparison
Incyte
NASDAQ
Loading...
Alnylam
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Incyte wins in 12 metrics, Alnylam wins in 6 metrics, with 0 ties. Incyte appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Incyte | Alnylam | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 19.55 | -209.81 | Alnylam |
| Price-to-Book Ratio | 3.90 | 236.81 | Incyte |
| Debt-to-Equity Ratio | 1.02 | 1,093.31 | Incyte |
| PEG Ratio | -0.10 | -0.72 | Alnylam |
| EV/EBITDA | 13.20 | -487.23 | Alnylam |
| Profit Margin (TTM) | 18.99% | -12.96% | Incyte |
| Operating Margin (TTM) | 25.63% | -2.09% | Incyte |
| EBITDA Margin (TTM) | 25.63% | N/A | N/A |
| Return on Equity | 24.30% | -257.83% | Incyte |
| Return on Assets (TTM) | 11.52% | -2.63% | Incyte |
| Free Cash Flow (TTM) | $235.17M | $-42.59M | Incyte |
| 1-Year Return | 27.84% | 72.02% | Alnylam |
| Price-to-Sales Ratio (TTM) | 3.57 | 24.12 | Incyte |
| Enterprise Value | $14.00B | $60.26B | Alnylam |
| EV/Revenue Ratio | 3.05 | 24.48 | Incyte |
| Gross Profit Margin (TTM) | 93.52% | 81.52% | Incyte |
| Revenue per Share (TTM) | $24 | $19 | Incyte |
| Earnings per Share (Diluted) | $4.29 | $-2.49 | Incyte |
| Beta (Stock Volatility) | 0.75 | 0.35 | Alnylam |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Incyte vs Alnylam Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Incyte | -0.48% | 5.66% | 0.35% | 26.57% | 38.42% | 24.09% |
| Alnylam | 0.07% | 2.54% | 3.13% | 39.79% | 72.77% | 97.32% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Incyte | 27.84% | 26.10% | -9.88% | -17.83% | 414.80% | 1,834.53% |
| Alnylam | 72.02% | 135.43% | 213.60% | 454.34% | 3,521.29% | 4,415.08% |
News Based Sentiment: Incyte vs Alnylam
Incyte
News based Sentiment: POSITIVE
September was a strong month for Incyte, highlighted by key FDA approvals for Opzelura, promising clinical trial data for povorcitinib, and increased analyst confidence reflected in raised price targets. These developments collectively strengthen the investment case and suggest continued growth potential, outweighing the minor concern of insider selling.
Alnylam
News based Sentiment: POSITIVE
October proved to be a strong month for Alnylam, highlighted by a significant milestone payment triggered by the start of a key Phase 3 trial and consistent analyst reports indicating the stock is significantly undervalued. These factors, combined with portfolio diversification efforts, create a positive outlook for the company.
Performance & Financial Health Analysis: Incyte vs Alnylam
| Metric | INCY | ALNY |
|---|---|---|
| Market Information | ||
| Market Cap | $16.38B | $60.43B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,887,920 | 969,587 |
| 90 Day Avg. Volume | 1,746,400 | 1,063,879 |
| Last Close | $86.28 | $460.99 |
| 52 Week Range | $53.56 - $88.66 | $205.87 - $484.21 |
| % from 52W High | -2.69% | -4.80% |
| All-Time High | $153.15 (Mar 13, 2017) | $484.21 (Sep 09, 2025) |
| % from All-Time High | -43.66% | -4.80% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.17% | 0.17% |
| Quarterly Earnings Growth | 0.16% | 0.17% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | -0.13% |
| Operating Margin (TTM) | 0.26% | -0.02% |
| Return on Equity (TTM) | 0.24% | -2.58% |
| Debt to Equity (MRQ) | 1.02 | 1,093.31 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $21.49 | $1.91 |
| Cash per Share (MRQ) | $12.40 | $21.80 |
| Operating Cash Flow (TTM) | $1.00B | $-15,539,000 |
| Levered Free Cash Flow (TTM) | $648.87M | $85.71M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Incyte vs Alnylam
| Metric | INCY | ALNY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 19.55 | -209.81 |
| Forward P/E | 13.66 | -371.32 |
| PEG Ratio | -0.10 | -0.72 |
| Price to Sales (TTM) | 3.57 | 24.12 |
| Price to Book (MRQ) | 3.90 | 236.81 |
| Market Capitalization | ||
| Market Capitalization | $16.38B | $60.43B |
| Enterprise Value | $14.00B | $60.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.05 | 24.48 |
| Enterprise to EBITDA | 13.20 | -487.23 |
| Risk & Other Metrics | ||
| Beta | 0.75 | 0.35 |
| Book Value per Share (MRQ) | $21.49 | $1.91 |
Financial Statements Comparison: Incyte vs Alnylam
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | INCY | ALNY |
|---|---|---|
| Revenue/Sales | $1.05B | $773.69M |
| Cost of Goods Sold | $73.20M | $142.95M |
| Gross Profit | $979.70M | $630.74M |
| Research & Development | $437.28M | $323.62M |
| Operating Income (EBIT) | $216.72M | $-16.20M |
| EBITDA | $270.13M | $35.44M |
| Pre-Tax Income | $234.19M | $-35.36M |
| Income Tax | $75.99M | $30.92M |
| Net Income (Profit) | $158.20M | $-66.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | INCY | ALNY |
|---|---|---|
| Cash & Equivalents | $1.94B | $1.02B |
| Total Current Assets | $3.51B | $3.27B |
| Total Current Liabilities | $1.72B | $1.08B |
| Long-Term Debt | $32.64M | $1.26B |
| Total Shareholders Equity | $3.67B | $115.44M |
| Retained Earnings | $-914.68M | $-7.35B |
| Property, Plant & Equipment | $287.08M | $695.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | INCY | ALNY |
|---|---|---|
| Operating Cash Flow | $251.93M | $-145.39M |
| Capital Expenditures | N/A | $-8.97M |
| Free Cash Flow | $262.90M | $-127.28M |
| Debt Repayment | $-1.09M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | INCY | ALNY |
|---|---|---|
| Shares Short | 8.70M | 3.72M |
| Short Ratio | 5.16 | 3.28 |
| Short % of Float | 0.06% | 0.04% |
| Average Daily Volume (10 Day) | 1,887,920 | 969,587 |
| Average Daily Volume (90 Day) | 1,746,400 | 1,063,879 |
| Shares Outstanding | 193.43M | 129.29M |
| Float Shares | 163.04M | 126.15M |
| % Held by Insiders | 0.02% | 0.04% |
| % Held by Institutions | 1.03% | 0.99% |
Dividend Analysis & Yield Comparison: Incyte vs Alnylam
| Metric | INCY | ALNY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |